Good News for Insomnia, Major Depression and Schizophrenia

By Chris Lange Updated Jan 11, 7:05AM EST · Published Aug 5, 3:45PM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Good News for Insomnia, Major Depression and Schizophrenia — © iLexx / Getty Images

Minerva Neurosciences, Inc. (NASDAQ: NERV) shares jumped on Monday after the company announced positive topline results from its two mid-stage studies in major depressive disorder (MDD) and insomnia. Specifically, these were two Phase 2b studies of seltorexant.

In the MDD study, the primary endpoint analysis showed a significant treatment effect at week 5 for seltorexant versus placebo. The efficacy signal for the 20 mg dose was statistically significant and more pronounced in the MDD population with sleep disorder.

These new findings show that seltorexant administered as monotherapy improves depressive symptoms and that the improvement is more pronounced when patients present with insomnia. Importantly, they also support the relationship between mood disorders, insomnia, hyper-arousal, clinical efficacy and the mechanism of action of seltorexant.

Separately, the firm announced positive top line results from a Phase 2b clinical trial of seltorexant in patients with insomnia disorder that demonstrated highly statistically significant and clinically meaningful improvement in the primary endpoint, Latency to Persistent Sleep (LPS) at Night 1.

[nativounit]

In addition to the primary endpoint, multiple secondary endpoints were improved with seltorexant versus placebo and standard of care zolpidem, available under the brand name Ambien. Furthermore, the beneficial effects of seltorexant on elderly patients, in conjunction with a favorable safety profile, suggest its potential benefit in the large and growing population of elderly patients whose prevalence of insomnia is higher than in younger patients.

Dr. Remy Luthringer, Executive Chairman and CEO of Minerva, commented:

In the first half of 2019, we presented positive data from two Phase 2b clinical trials with seltorexant. In addition, in a recent biomarker study with seltorexant, we demonstrated mood improvements in MDD patients when seltorexant was given as monotherapy. Taken together, the data from these studies point to the unique ability of seltorexant to address unmet medical needs in both depression and insomnia as an adjunctive treatment or in monotherapy.

Shares of Minerva were last seen up over 8% at $6.99, with a 52-week range of $4.07 to $12.95. The consensus analyst price target is $19.75.

[wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.